Citations

Showing 10 of 108094 citations.

Is it time for a more ‘proactive’ approach to metastatic prostate cancer?
Soligo, Matteo, Sharma, Vidit , Karnes, R. Jeffrey

Mayo Clinic

BJU International | January 23, 2018 | Volume: 121 | Issue: 2 | Pages: 167-168

10.1111/bju.14107 | PMID 29359528 Get It

Selecting patients for prostate cancer treatment: the role of comorbidity
Satkunasivam, Raj , Bhindi, Bimal , Wallis, Christopher J D

Mayo Clinic

BJU International | January 23, 2018 | Volume: 121 | Issue: 2 | Pages: 164-165

10.1111/bju.13923 | PMID 29359530 Get It

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016
Li, Hongli , Leonard, John P. , Kaminski, Mark , Braziel, Rita M., Spier, Catherine, Maloney, David G. , Cheson, Bruce D. , Dakhil, Shaker R. , Smith, Sonali M. , Fisher, Richard I., Friedberg, Jonathan W. , Rimsza, Lisa, Kaminski, Mark S, Spier, Catherine M, Gopal, Ajay K. , Dakhil, Shaker, Press, Oliver W. , Shadman, Mazyar , Rimsza, Lisa M. , LeBlanc, Michael

Mayo Clinic

Journal of Clinical Oncology | January 22, 2018 | Volume: 36 | Issue: 7 | Pages: 697-703

10.1200/jco.2017.74.5083 | PMID 29356608 Get It

Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133–tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81%; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-term follow-up of alternative approaches demonstrates superiority.
Response by Obokata and Borlaug to Letters Regarding Article, “Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction”
Obokata, Masaru , Borlaug, Barry A. , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

Circulation | January 22, 2018 | Volume: 137 | Issue: 4 | Pages: 416-417

10.1161/circulationaha.117.031394 | PMID 29358350 Get It

Comparison of long‐term clinical outcomes among different vascularized lymph node transfers: 6‐year experience of a single center's approach to the treatment of lymphedema
Ciudad, Pedro , Agko, Mouchammed , Manrique, Oscar J. , Chang, Wei‐Ling , Huang, Tony Chieh‐Ting , Mouchammed, Agko , Huang, Tony C. T., Huang, Tony C T , Chen, Hung‐Chi

Mayo Clinic

Journal of Surgical Oncology | January 22, 2018 | Volume: 117 | Issue: 6 | Pages: 1346-1347

10.1002/jso.24957 | PMID 29357118 Get It

In response to socioeconomic disparities and comorbidities, not race, affect salivary gland malignancy survival outcomes
Aponte‐Ortiz, Jaime A. , Greenberg, Alexandra J. , Janus, Jeffrey R. , Greenberg-Worisek, Alexandra J

Mayo Clinic

The Laryngoscope | January 22, 2018 | Volume: 128 | Issue: 9 | Pages: No page available

10.1002/lary.27091 | PMID 29355965 Get It

Inflammatory potential of diet and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Zheng, Jiali , Wirth, Michael D. , Antwi, Samuel O. , Shoaibi, Azza , Shivappa, Nitin , Antwi, Samuel O , Shivappa, Nitin , Merchant, Anwar T. , Zhang, Jiajia , Stolzenberg‐Solomon, Rachael Z. , Hébert, James R. , Steck, Susan E.

Mayo Clinic

International Journal of Cancer | January 22, 2018 | Volume: 142 | Issue: 12 | Pages: 2461-2470

10.1002/ijc.31271 | PMID 29355939 Get It

Inflammation plays a central role in pancreatic cancer etiology and can be modulated by diet. We aimed to examine the association between the inflammatory potential of diet, assessed with the Dietary Inflammatory Index (DII®), and pancreatic cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial prospective cohort. Our study included 101,449 participants aged 52–78 years at baseline who completed both baseline questionnaire and a diet history questionnaire. Energy‐adjusted DII (E‐DII) scores were computed based on food and supplement intake. Cox proportional hazards models and time dependent Cox models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) with participants in the lowest E‐DII quintile (most anti‐inflammatory scores) as referent. After a median 8.5 years of follow‐up, 328 pancreatic cancer cases were identified. E‐DII scores were not associated with pancreatic cancer risk in the multivariable model (HRQ5vsQ1 = 0.94; 95% CI = 0.66–1.35; p‐trend = 0.43). Time significantly modified the association (p‐interaction = 0.01). During follow up <4 years, there was suggestive evidence of an inverse association between E‐DII and pancreatic cancer (HRQ5vsQ1 = 0.60; 95% CI = 0.35–1.02; p‐trend = 0.20) while there was a significant positive trend in the follow up ≥4 years (HRQ5vsQ1 = 1.31; 95% CI = 0.83–2.08; p‐trend = 0.03). Similar results were observed for E‐DII from food only. Our study does not support an association between inflammatory potential of diet and pancreatic cancer risk; however, heterogeneous results were obtained with different follow‐up times. These divergent associations may result from the influences of undetected disease in the short‐term.
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27
Strasser‐Weippl, Kathrin , Higgins, Michaela J. , Chapman, Judith‐Anne W. , Budd, G. Thomas , Badovinac-Črnjević, Tanja, Han, Lei , Rabaglio, Manuela , Elliott, Catherine, Shepherd, Lois E. , Goss, Paul E. , Ingle, James N. , Rabaglio-Poretti, Manuela , Sledge, George W. , Ellis, Matthew J. , Pritchard, Kathleen I. , Clemons, Mark J. , Han, Lei, Gelmon, Karen A.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 22, 2018 | Volume: 110 | Issue: 9 | Pages: 1003-1008

10.1093/jnci/djy017 | PMID 29554282 Get It

Abstract Background Celecoxib and low-dose aspirin might decrease risk of breast cancer recurrence. Methods In the Canadian Cancer Trials Group MA.27, postmenopausal hormone receptor–positive breast cancer patients were randomly assigned (2 × 2) to adjuvant exemestane or anastrozole, and celecoxib or placebo. Low-dose aspirin of 81 mg or less was a stratification factor. Due to concerns about cardiac toxicity, celecoxib use was stopped in December 2004, while stratification by aspirin use was removed through protocol amendment. We examined the effects of celecoxib and low-dose aspirin on event-free survival (EFS), defined as time from random assignment to time of locoregional or distant disease recurrence, new primary breast cancer, or death from any cause; distant disease–free survival (DDFS); and overall survival (OS). All statistical tests were two-sided. Results Random assignment to celecoxib (n = 811, 50.0%) or placebo (n = 811, 50.0%) was discontinued after 18 months (n = 1622). At a median of 4.1 years’ follow-up, among 1622 patients, 186 (11.5%) patients had an EFS event: 80 (4.9%) had distant relapse, and 125 (7.7%) died from any cause. Celecoxib did not statistically significantly impact EFS, DDFS, or OS in univariate analysis (respectively, P = .92, P = .55, and P = .56) or multivariable analysis (respectively, P = .74, P = .60, and P = .76). Low-dose aspirin use (aspirin users n = 476, 21.5%; non–aspirin users n = 1733, 78.5%) was associated in univariate analyses with worse EFS (hazard ratio [HR] = 1.48, 95% confidence interval [CI] = 1.12 to 1.96, P = 0.006) and worse OS (HR = 1.87, 95% CI = 1.35 to 2.61, P < .001). After adjusting for baseline characteristics and treatment arm, aspirin use showed no statistical association with EFS (P = .08) and DDFS (P = .82), but was associated with statistically worse OS (HR = 1.67, 95% CI = 1.13 to 2.49, P = .01). Conclusion Random assignment to short-term (≤18 months) celecoxib as well as use of low-dose aspirin showed no effect on DDFS and EFS in multivariable analysis. Low-dose aspirin increased “all-cause” mortality, presumably because of higher preexisting cardiovascular risks.
Adult presentation of ALCAPA: Echo and CT diagnosis
Kerut, Edmund Kenneth , Kogos, Philip G., Turner, Michael C. , Ascuitto, R.J. , Ross‐Ascuitto, Nancy, Said, Sameh M. , Anderson, Jason H. , Turner, Michael

Mayo Clinic

Echocardiography | January 22, 2018 | Volume: 35 | Issue: 7 | Pages: 1045-1048

10.1111/echo.13807 | PMID 29356089 Get It

A healthy 20‐year‐old male presented with aborted sudden death. Both thoracic echocardiography and cardiac computed tomographic angiography demonstrated the characteristic findings of ALCAPA noting a dilated and tortuous right coronary artery, dilated coronary collateral arteries within the interventricular septum or along the surface of the heart, and visualization of the left coronary artery origin from the posterior aspect of the main pulmonary artery. Both imaging modalities demonstrated all three characteristic findings of this rare coronary anomaly and served as complementary imaging studies for surgical correction.